QIAGEN Receives FDA Clearance for First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms

Wednesday, January 24, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Expanded use of ipsogen test provides diagnostic testing needs for all myeloproliferative neoplasms in line with the latest WHO guidelines

HILDEN, Germany, and GERMANTOWN, Maryland, January 23, 2018

/PRNewswire/ --

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs), which are a group of cancers in which immature blood cells in the bone marrow do not mature and become healthy blood cells.

Click here for the full press release

https://corporate.qiagen.com/newsroom/press-releases/2017/20180119_ipsogen_jak2?sc_lang=en

Contacts: QIAGEN Investor Relations John Gilardi e-mail: ir@QIAGEN.com +49-2103-29-11711 Public Relations Dr. Thomas Theuringer e-mail: pr@QIAGEN.com +49-2103-29-11826

SOURCE Qiagen N.V.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store